# US 2026/0263532 A1 · Krill oil composition enriched in lpc-dha and lpc-epa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263532 A1
- Document ID: US20260263532A1
- Status: Published application
- Kind: A1
- Application number: 19/342,923
- Filed: 2025-09-29
- Published: 2026-09-10
- Earliest claimed: 2020-03-31
- Assignees: Aker Biomarine Human Ingredients AS; The Board of Trustees of the University of Illinois
- Applicants: Aker BioMarine Human Ingredients AS; The Board of Trustees of the University of Illinois
- Inventors: Finn Myhren; Petter-Arnt Hals; Nils Hoem; Andreas Berg Storsve; Papasani V. Subbaiah; Poorna Yalagala; Sugasini Dhavamani; Leon Tai
- Web page: https://patentgrep.com/patent/US20260263532A1

## CPC

- A61K 35/612: Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61P 27/02: Ophthalmic agents
- C12P 7/6463: obtained from glyceride producing microorganisms, e.g. single cell oil
- C12P 9/00: Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen {(phosphoglycerides, C12P7/6481)}
- C12Y 301/01003: Triacylglycerol lipase (3.1.1.3)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.

## Claims

### Claim 1

A method for treating a neurological disease selected from the group consisting of Parkinson's, schizophrenia, traumatic brain injury, stroke and Alzheimer's in a subject in need thereof comprising:
administering to the subject in need thereof an effective amount of a formulation comprising a lysophosphatidylcholine (LPC) composition comprising a LPC-compound selected from the group consisting of any one of formulas 1 to 8, and any combination thereof, so that the symptoms of the disease or condition are improved, controlled, reduced, or alleviated:
wherein:
R1 is OH or —OC(O)(CH2)nCH3;
R2 is OH or —OC(O)(CH2)nCH3; and
n is 0, 1, or 2;
and wherein the molar ratio of lysoPC-DHA:lysoPC-EPA is in the range of from 3:1 to 1:5;
and further wherein
i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA plus the number of moles 2-lysoPC-EPA; and
ii) ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA plus the number of moles 2-lysoPC-DHA.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 is OH and R2 is OH.

### Claim 3 (depends on 1, 6)

The method according to claim 1, with the proviso that: if the LPC composition comprises i) a compound according to formula 1, wherein R2 is OH; and/or ii) a compound according to formula 3, wherein R1 is OH; then the LPC composition further comprises at least one of the other LPC-compounds referred to in claim 6.

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more LPC-compound is:
a compound according to formula 1; and/or a compound according to formula 3; and
a compound according to formula 2; and/or a compound according to formula 4.

### Claim 5 (depends on 1)

The method of claim 1, wherein
R1 and R2 are OH; and
the molar ratio of lysoPC-DHA:lysoPC-EPA is from 1:1 to 3:1 wherein i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA+the number of moles 2-lysoPC-EPA; and ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA+the number of moles 2-lysoPC-DHA.

### Claim 6 (depends on 1)

The method of claim 1, wherein the disease is Alzheimer's.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease is Parkinson's.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administering is by a mode selected from the group consisting of oral administration and intravascular administration.

### Claim 9 (depends on 8)

The method of claim 8, wherein the mode of administration is oral administration.

### Claim 10 (depends on 8)

The method of claim 8, wherein the mode of administration is intravascular administration.

### Claim 11 (depends on 1)

The method of claim 1, wherein the LPC composition in the formulation comprises an amount of total LPC from 10% to 100% by weight of the LPC composition.

### Claim 12 (depends on 1)

The method of claim 1, wherein the LPC composition comprises an additional lipid different from LPC.

### Claim 13 (depends on 12)

The method of claim 12, wherein the additional lipid is selected from the group consisting of triglycerides, free fatty acids, ethyl esters and phospholipids selected from the group consisting of phosphatidylethanolamine and phosphatidylcholine.

### Claim 14 (depends on 13)

The method of claim 13, wherein the LPC composition comprises a predominant amount of the LPC-compound compared to an amount of phosphatidylcholine.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is a mammalian subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is a human subject.

### Claim 17 (depends on 1)

The method of claim 1, wherein
R1 and R2 are OH; and
the molar ratio of lysoPC-DHA:lysoPC-EPA is from 3:1 to 1:5; wherein i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA+the number of moles 2-lysoPC-EPA; and ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA+the number of moles 2-lysoPC-DHA.
